Advancing Women’s Health Through Focused Drug Development

Gesthera’s development strategy is centered on women’s health and on therapeutic areas where current treatment options remain limited. The company’s first priority is spontaneous preterm labor, with GST001 positioned as its lead clinical program. The current strategy focuses on developing GST001 as a monotherapy and on earlier gestational ages, particularly below 32 weeks, where Gesthera […]

GST001: A Targeted Approach to Preterm Labor

GST001 is Gesthera’s lead development program for spontaneous preterm labor. It is described as a novel, orally available small molecule that selectively targets the prostaglandin F2α receptor. The development rationale is based on targeting inflammation and uterine contractions while aiming to reduce some of the fetal risks associated with non-specific prostaglandin inhibition. This selective mechanism […]

Preterm Labor: Why Every Hour Matters

Preterm labor remains a major challenge in obstetrics. According to the Gesthera presentation, preterm birth represented around 10% of births worldwide in 2020 and remains associated with significant neonatal morbidity and mortality, particularly at earlier gestational ages. In acute preterm labor, even a short delay in delivery can be clinically important. A 48-hour prolongation of […]